Cargando…
Correction: Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma
Autores principales: | Ma, Heng, Feng, Peng-Hui, Yu, Shuang-ni, Lu, Zhao-Hui, Yu, Qi, Chen, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153199/ https://www.ncbi.nlm.nih.gov/pubmed/35637429 http://dx.doi.org/10.1186/s12885-022-09692-0 |
Ejemplares similares
-
Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma
por: Ma, Heng, et al.
Publicado: (2022) -
Correction: P-Glycoprotein Acts as an Immunomodulator during Neuroinflammation
por: Kooij, Gijs, et al.
Publicado: (2010) -
Correction: Identification and validation of early genetic biomarkers for apple replant disease
por: Rohr, Annmarie-Deetja, et al.
Publicado: (2022) -
Author Correction: Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis
por: Berg, Hege F., et al.
Publicado: (2021) -
Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
por: Segura-Collar, Berta, et al.
Publicado: (2023)